Ninlaro

Active Ingredient(s): Ixazomib
FDA Approved: * November 20, 2015
Pharm Company: * MILLENNIUM PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ninlaro Overview

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer,[2] in combination with other drugs. It is taken by mouth in form of capsules. Common side effects include diarrhoea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda....

Read more Ninlaro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ixazomib

Recent Ninlaro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ixazomib
  • Capsule: 2.3mg, 3mg, 4mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ninlaro: (3 results)

Sorted by National Drug Code
  • 63020-078 Ninlaro 2.3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-079 Ninlaro 3 mg Oral Capsule by Millennium Pharmaceuticals, Inc.
  • 63020-080 Ninlaro 4 mg Oral Capsule by Millennium Pharmaceuticals, Inc.

Other drugs which contain Ixazomib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA